peptidechats
Research information only. Not medical advice. 18+ only. Not FDA-approved for human therapeutic use.

Ganirelix

Also known as: Orgalutran, Antagon, ganirelix acetate, Org 37462, GnRH antagonist (third-generation decapeptide)

GnRH receptor antagonist — synthetic third-generation decapeptide; assisted reproduction pituitary-suppression agent

Research chemicalLast updated: October 10, 2026Based on 4 peer-reviewed studiesPreclinical data only — no human trials
Ask about Ganirelix in chat →

What it is

Ganirelix (Orgalutran, Antagon) is a daily injection used during IVF cycles to stop the body from releasing eggs too early. By blocking a key hormone signal in the pituitary gland, it keeps the ovaries under the fertility team's control so more mature eggs can be collected at the right time.

The scientific side

ganirelix is a synthetic third-generation decapeptide gonadotropin-releasing hormone (GnRH) antagonist that acts by competitive binding at GnRH receptors in the anterior pituitary gland. By occupying these receptors without activating them, ganirelix immediately and dose-dependently blocks endogenous GnRH from stimulating the synthesis and release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This competitive inhibition is the fundamental distinction from GnRH agonists: agonists initially stimulate GnRH receptors before causing downregulation, producing a transient hormone surge; ganirelix produces immediate suppression from the first dose with no such flare. The clinical consequence in ART is rapid, controllable prevention of premature LH surges that would otherwise trigger spontaneous ovulation and abort the stimulation cycle before oocyte retrieval. A daily dose of 0.25 mg was selected after Phase II dose-finding studies as the minimum effective daily dose to reliably prevent premature LH surges while achieving the highest ongoing pregnancy rate per started cycle. After subcutaneous injection, ganirelix is rapidly absorbed, reaching peak plasma concentrations within one to two hours. A pituitary sensitizing effect has been described with multi-day ganirelix administration: after eight days of 0.5 mg daily ganirelix in postmenopausal women, pituitary LH response to a supramaximal GnRH test dose increased significantly (median delta-LH30 from 65.5 to 77.5 IU/L; p=0.002), potentially explaining the gradual LH escape phenomenon observed in some IVF cycles during prolonged antagonist use. At the granulosa cell level, in vitro data from human granulosa-lutein cells demonstrate that 1 nM ganirelix does not significantly alter basal or hCG-stimulated cyclic AMP accumulation, suggesting ganirelix exerts its primary contraceptive-prevention effects through the pituitary rather than through direct intrafollicular cAMP signaling. In an experimental mouse blastocyst model, ganirelix acetate inhibited preimplantation embryo development and induced mitochondria-mediated apoptosis in blastocysts — an effect reversed by co-treatment with GnRH agonist — indicating GnRH receptor expression and autocrine signaling in the preimplantation embryo, with potential implications for embryo quality considerations in ART protocols.

Class: GnRH receptor antagonist — synthetic third-generation decapeptide; assisted reproduction pituitary-suppression agent

Administration & storage

Administration
Subcutaneous injection into the lower abdomenpreferably around the navel areaavoiding the periumbilical zone; upper thigh may also be usedPinch a fold of skin and insert the needle at a 45-degree angle; inject the solution slowlySite rotation is recommended with each daily injection to minimize local reactionsSelf-administration by the patient after appropriate training from a clinician is the standard practice in IVF cycles
Storage
Store at 2–8°C (refrigerated) or at room temperature up to 25°C (77°F) for a limited period as specified in the product labeling. Do not freeze. Keep in original packaging to protect from light. Discard any unused portion; single-use syringe only.
Cautions
Ovarian hyperstimulation syndrome (OHSS) is the most serious complication associated with ganirelix use in the context of ART; it arises from the gonadotropin stimulation component of the protocol rather than from ganirelix itself, but ganirelix use does not eliminate OHSS risk. The 20-year FAERS pharmacovigilance analysis (n=1,096 ADE reports) identified OHSS as the strongest signal (n=290 reports, ROR 2462.76).,Injection site reactions are the most common adverse effects: pain, erythema, bruising, pruritus, and swelling at the injection site. Reported in the majority of patients in clinical trials. Generally mild and transient.,Fetal harm and pregnancy loss: ganirelix is not indicated for use in pregnant women. Animal studies demonstrate embryofetal toxicity. A pharmacovigilance signal for fetal death was identified in FAERS (n=6 reports, ROR 21.05). If pregnancy is confirmed during or shortly after ganirelix treatment, the drug should be discontinued and the patient counseled.,Potential apoptotic effect on preimplantation embryos: in vitro mouse blastocyst studies demonstrated that ganirelix acetate induced mitochondria-mediated apoptosis and inhibited embryo development at the expanded blastocyst stage, effects reversible by GnRH agonist co-treatment. Clinical significance in human ART is uncertain but the finding is a recognized area of investigation.,LH escape during prolonged administration: a pituitary sensitizing effect with multi-day ganirelix use has been demonstrated, potentially leading to breakthrough LH rises in a subset of patients. Monitoring of serum LH and estradiol during stimulation is recommended.,Hypersensitivity reactions: the 20-year FAERS analysis identified hypersensitivity-related signals including urticaria, rash, and anaphylactic-type reactions. Ganirelix is contraindicated in patients with known hypersensitivity to ganirelix or any excipient (including mannitol), and in patients with hypersensitivity to GnRH or GnRH analogues.,Pharmaceutical impurities in prefilled syringes: studies have identified acrylic acid-ganirelix adduct impurities leaching from the needle adhesive in prefilled syringes, as well as N-(2-carboxyethyl)-ganirelix adduct impurities accumulating to approximately 0.3% over six months of storage. These impurity signals are under active investigation for toxicological significance. (PMIDs: 38796153, 38131153)

Legal & regulatory status

US FDA

FDA-approved (NDA 021057) as Antagon (ganirelix acetate injection) 250 mcg/0.5 mL for the inhibition of premature LH surges in women undergoing controlled ovarian hyperstimulation. Approved June 1999. Administered as a…

WADA

Ganirelix is prohibited under the WADA Prohibited List for female athletes. GnRH antagonists fall under Section S4 (Hormone and Metabolic Modulators) — agents modulating gonadotropin secretion and sex hormone levels are…

Health Canada

Approved in Canada as Orgalutran (ganirelix acetate injection) for prevention of premature LH surges during controlled ovarian stimulation in women undergoing ART including IVF and ICSI. Regulatory approval is…